Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed … – Business Wire (press release)
|
Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed …
Business Wire (press release) To the company's knowledge, this is the first polyvalent immunotherapy cleared by the FDA that targets the blood vessels that feed cancer. ValloVax was inspired by the original research of Dr. Valentin Ivanovich Govallo who observed tumor regression of … |
